Gannex reveals positive data from ASC41 clinical study in 20 subjects
Category: #health  By Pankaj Singh  Date: 2021-02-22
  • sharesocial_share_icon
  • Twitter
  • Facebook
  • LinkedIn

Gannex reveals positive data from ASC41 clinical study in 20 subjects

Ascletis Pharma Inc.’s wholly-owned company, Gannex, has reportedly announced the positive clinical data from its ASC41 trial conducted among overweight and obese subjects. The active metabolite of this liver-targeted prodrug is selective THR-β (thyroid hormone receptor beta) agonist.

In the clinical trial, 20 overweight & obese subjects with LDL-C (low-density lipoprotein cholesterol) were examined. They are treated with 10 mg oral tablets of ASC41 or matching placebo tablets once in a week in this double-blind, randomized, placebo-controlled clinical trial.

As per the preliminary data, following nearly 28 days of oral dosing, the study participants demonstrated a clinically meaningful, sustainable, and statistically significant reduction in TG (triglyceride), LDL-C, and TC (total cholesterol), as compared to placebo. Additionally, the level of HDL-C (high-density lipoprotein cholesterol) remained relatively unchanged.

In this clinical study, there has been a relatively benign adverse event profile of ASC41. Majority of the adverse reactions were grade 1 or 2, with only three grade 3 cases (two in the ASC41 group and one in the placebo group). In addition, there were no serious adverse reactions.

According to Gannex’s Chief Medical Officer, Melissa Palmer, MD, the company showed excitement towards the completion of the ASC41 study among overweight and obese subjects suffering from elevated LDL-C, as they are prone to NAFLD (nonalcoholic fatty liver disease). The recently announced clinical data provided crucial safety and preliminary efficacy readouts that will enable it to advance the clinical program further to evaluate patients with NASH.

As per the statement made by the Founder, Chairman, & CEO of Ascletis, Dr. Jinzi J. Wu, the company has been rapidly advancing its NASH pipeline with 3 targets namely FXR, THR-β, and FASN. This is evident from the positive results of the ASC41 trial conducted among overweight and obese participants, as well as its participation in Sagimet’s recent $80 million crossover financing round led by global premium investors.

Source credit:

https://www.prnewswire.com/news-releases/gannex-announces-positive-clinical-results-in-overweight-and-obese-subjects-for-its-thr--agonist-asc41-301232070.html



About Author

Pankaj Singh

Email: [email protected]   linkdin twitter

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

More News By Pankaj Singh

BPOC joins hands with SPCP to expand access to healthcare services

BPOC joins hands with SPCP to expand access to healthcare services

By Pankaj Singh

Healthcare-focused private equity company BPOC has recently inked a collaboration with Dr. Thomas Bat, in order to form a regionally focused primary case MSO (management services organization). SPCP (Southeast Primary ...

MercadoLibre planning to double workforce amid e-commerce boom

MercadoLibre planning to double workforce amid e-commerce boom

By Pankaj Singh

MercadoLibre Inc., an Argentinian e-commerce firm, has reportedly planned to bump up their workforce this year. The company has also invested USD 1.1 billion for expanding their services and warehouse space in Mexico, ...

Vesta Healthcare raises $65M for home healthcare transformation

Vesta Healthcare raises $65M for home healthcare transformation

By Pankaj Singh

Leading digital health and 24/7 clinical provider, Vesta Healthcare, has reportedly secured nearly $65M in a financing led by Deerfield Management Company. The event also saw participation from existing investors, such...